FN2 Earnings Intelligence
Guardant Health, Inc. income statement
Guardant Health, Inc. (GH) Income Statement (annual) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $492.2 | $141.6 | $1,133.5 | $525.5 | $378.2 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $373.7 | $449.5 | $563.9 | $739 | $982 | $1,357.6 | $1,838.1 |
| % Growth | 30.3% | 20.3% | 25.5% | 31.0% | 32.9% | 38.2% | 35.4% |
| Gross Profit | - | - | - | - | $633 | - | - |
| % Margin | - | - | - | - | 64.5% | - | - |
| EBITDA | -$388.7 | -$508.4 | -$521.8 | -$401.2 | -$397.5 | - | - |
| % Margin | -104.0% | -113.1% | -92.5% | -54.3% | -40.5% | - | - |
| Net Income | -$384.8 | -$654.6 | -$479.4 | -$436.4 | -$416.3 | - | - |
| % Margin | -103.0% | -145.6% | -85.0% | -59.0% | -42.4% | - | - |
| Diluted EPS | -$4.00 | -$6.41 | -$4.28 | -$3.56 | -$3.32 | -$3.25 | -$2.12 |
| % Growth | - | -60.2% | 33.2% | 16.8% | 6.7% | 2.2% | 34.7% |
| Operating Cash Flow | -$209 | -$309.5 | -$325 | -$239.9 | -$184.8 | - | - |
| CapEx | $75 | $77.5 | $20.5 | $35.1 | $48.3 | - | - |
| Free Cash Flow | -$284.1 | -$386.9 | -$345.5 | -$274.9 | -$233.1 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $373.7 | $449.5 | $563.9 | $739 | $982 | $1,357.6 | $1,838.1 |
| Gross Profit | - | - | - | - | $633 | - | - |
| EBITDA | -$388.7 | -$508.4 | -$521.8 | -$401.2 | -$397.5 | - | - |
| Net Income | -$384.8 | -$654.6 | -$479.4 | -$436.4 | -$416.3 | - | - |
| Diluted EPS | -$4.00 | -$6.41 | -$4.28 | -$3.56 | -$3.32 | -$3.25 | -$2.12 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $492.2 | $141.6 | $1,133.5 | $525.5 | $378.2 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $1,134.8 | $1,137.4 | $1,140 | $1,142.5 | $1,504 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$209 | -$309.5 | -$325 | -$239.9 | -$184.8 |
| Capital Expenditure | $75 | $77.5 | $20.5 | $35.1 | $48.3 |
| Free Cash Flow | -$284.1 | -$386.9 | -$345.5 | -$274.9 | -$233.1 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 30.3% | 20.3% | 25.5% | 31.0% | 32.9% |
| Gross Margin | - | - | - | - | 64.5% |
| EBITDA Margin | -104.0% | -113.1% | -92.5% | -54.3% | -40.5% |
| Net Margin | -103.0% | -145.6% | -85.0% | -59.0% | -42.4% |
| FCF Margin | -76.0% | -86.1% | -61.3% | -37.2% | -23.7% |
| Diluted EPS Growth | - | -60.2% | 33.2% | 16.8% | 6.7% |
Get the GH recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.